NL-OMON26753招募中不适用
The cost-effectiveness of abatacept, rituximab or anti-TNF alpha for patients with rheumatoid arthritis.
Department of Rheumatology, University Medical Centre Sint Radboud0 个研究点目标入组 132 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 132
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. RA diagnosis according to ACR criteria;
- •2. Having been treated adequately with one of the anti-TNF alpha agents with insufficient effects;
排除标准
- •1. Former treatment with abatacept or rituximab;
- •2. Patient's or physician's preference for one of the agents;
研究者
相似试验
尚未招募
不适用
The cost-effectiveness of abatacept, rituximab or anti-TNF alpha for patients with rheumatoid arthritisrheumatoid arthritisNL-OMON32522niversitair Medisch Centrum Sint Radboud261
进行中（未招募）
不适用
The cost-effectiveness of abatacept, rituximab or anti-TNF alpha for patients with rheumatoid artritis. - Dutch Rheumatoid Arthritis Monitoring (DREAM) Targetted Immune Modulator Evaluation (TIME)MedDRA version: 12.0Level: PTClassification code 10039073Term: Rheumatoid arthritisRheumatoid arthritisEUCTR2008-005450-20-BERadboud University Nijmegen Medical Centre, department of Rheumatic Diseases261
已完成
不适用
A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and CancerThromboembolismNCT05643885Pfizer7,304
进行中（未招募）
1 期
Comparison of two treatments rituximab in patients with autoimmune disease resistant to conventional treatmentsEUCTR2011-005856-32-ESFundación Progreso y Salud9
已完成
Unknown
Cost-effectiveness study of atezolizumab vs. durvalumab : real-world data on first-line chemotherapy combined with immune-checkpoint inhibitors for extensive disease small-cell lung cancerextensive disease small cell lung cancerJPRN-UMIN000053483Kobe Minimally Invasive Cancer Center200